Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

BACKGROUND: We explored whether serum cytokines could be used as biomarkers for optimal use of tumor necrosis factor inhibitors (TNF-i) and interleukin (IL)-17 inhibitors (IL-17-i) in patients with psoriatic arthritis (PsA). METHODS: In cohort 1 (47 patients treated with IL-17-i [n=23] or TNF-i [n=2...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagawa, Ippei, Nakayamada, Shingo, Ueno, Masanobu, Miyazaki, Yusuke, Iwata, Shigeru, Kubo, Satoshi, Sonomoto, Koshiro, Anan, Junpei, Ohkubo, Naoaki, Inoue, Yoshino, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011943/
https://www.ncbi.nlm.nih.gov/pubmed/35428323
http://dx.doi.org/10.1186/s13075-022-02771-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011943/
https://www.ncbi.nlm.nih.gov/pubmed/35428323
http://dx.doi.org/10.1186/s13075-022-02771-4

Ejemplares similares